Literature DB >> 9247101

Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment.

L R Holsti1, S Pyrhönen, M Kajanti, M Mäntylä, K Mattson, P Maasilta, L Kivisaari.   

Abstract

Malignant pleural mesothelioma is a rare malignancy with a bleak prognosis. The role of radiotherapy has not yet been clarified. Our aim was to study the effect of altered fractionation on mesothelioma. We have treated 57 patients, 41 males and 16 females, with hemithorax irradiation with six different fractionation schedules. All the patients have been included in a combined modality program consisting of surgery followed by chemotherapy and finally by hemithorax irradiation. The radiotherapy schedules used were: I. Conventional fractionation of 20 Gy in 10 fractions over 12 days. II. Split-course radiotherapy 55 Gy in 25 fractions of 2.2 Gy over 7 weeks (a two weeks rest halfways) followed by a boost dose of 15 Gy over 8 days to the major tumour area. III. Hyperfractionation of 70 Gy over 7 weeks, 1.25 Gy BID with a 6-h interval and a 10-day rest halfways. IV. Combined hyperfractionation and hypofractionation, 35 Gy hyperfractionation in 28 fractions (1.25 Gy BID with a 6-h interval) over three weeks followed by 36 Gy hypofractionation 9 fractions of 4 Gy given every other day over 3 weeks to the major tumour areas only. V. Hypofractionation of 38.5 Gy over 15 days (9 x 3.5 Gy). VI. Combined conventional radiotherapy and hypofractionation with 20 Gy given conventionally in 10 fractions followed by 10 fractions of 3 Gy over two weeks, overall time 4 weeks. The 2-year survival rate of all patients was 21% and the 5-year survival rate 9%. Two patients are still alive more than 6 and 9 years after radiotherapy. Progression occurred after surgery in four patients, during and after chemotherapy in 22 patients and after completed radiotherapy in 29 patients. The pattern of progression was similar in each treatment group.

Entities:  

Mesh:

Year:  1997        PMID: 9247101     DOI: 10.3109/02841869709001287

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

Review 1.  What is the role of radiotherapy in malignant pleural mesothelioma?

Authors:  Allan Price
Journal:  Oncologist       Date:  2011-02-23

2.  FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.

Authors:  Victor H Gerbaudo; Marcelo Mamede; Beatrice Trotman-Dickenson; Hiroto Hatabu; David J Sugarbaker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

3.  Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.

Authors:  Andreas Rimner; Daniel E Spratt; Marjorie G Zauderer; Kenneth E Rosenzweig; Abraham J Wu; Amanda Foster; Ellen D Yorke; Prasad Adusumilli; Valerie W Rusch; Lee M Krug
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-26       Impact factor: 7.038

4.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

Review 5.  Radiotherapy for malignant pleural mesothelioma.

Authors:  E Chapman; E G Berenstein; M Diéguez; Z Ortiz
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.